Patent ID: 7833513
Filing Date: 2010-11-16
Classification: A61K,G01N

Abstract:
1. A method for reducing neurodegeneration in a human subject suffering from mild cognitive impairment or Alzheimer's Disease, said method comprising the steps of: a) assessing the level of cognitive impairment and determining the level of at least one factor in the insulin/insulin-like growth factor (IGF) signaling pathway in said subject; b) administering to said subject a therapeutically effective amount of a peroxisome proliferator-activated receptor (PPAR) δ receptor selective agonist, in an amount effective to increase the level of sensitivity to insulin in the brain of said subject; and c) re-assessing the level of cognitive impairment and the level of the at least one factor in the insulin/IGF signaling pathway in said subject; whereby a reduction in the level of cognitive impairment and an increase in the level of the factor in the insulin/IGF signaling pathway after administration of the PPAR δ receptor selective agonist is indicative of increased sensitivity to insulin and thereby reduced neurodegeneration.